Phase I trial with a combination of docetaxel +153 Sm-EDTMP (Samarium 153) [samarium-153 SM lexidronam] in patients with hormone-refractory prostate cancer
Phase of Trial: Phase I
Latest Information Update: 23 May 2018
At a glance
- Drugs Docetaxel (Primary) ; Samarium 153 lexidronam (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 16 Dec 2008 Planned patient number changed from 12 to 13 as reported by ClinicalTrials.gov.
- 16 Dec 2008 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.